| |
Patients
|
Controls
|
|---|
|
(n = 52) (100%)
|
(n = 52) (100%)
|
|---|
|
Age (years)
|
47.36 ± 12.45
|
49.09 ± 11.48
|
|
Sex (female)
|
49 (94.23%)
|
48 (92.31%)
|
|
Duration of disease (years)
|
4.53 ± 4.64
|
NA
|
|
Education (years)
|
9.32 ± 4.91
|
11.05 ± 5.37
|
|
Smoking
|
0
|
0
|
|
Objective ocular involvement
|
45 (86.54%)
| |
|
Objective oral involvement
|
40 (76.92%)
| |
|
Positive salivary gland biopsy
|
39 (75%)
| |
|
ESR (mm after 1 h)
|
34.38 ± 21.39
| |
|
CRP (mg/L)
|
11.95 ± 10.36
| |
|
ANA
|
43 (82.69%)
| |
|
Anti-SSA antibody
|
41 (78.84%)
| |
|
Anti-SSB antibody
|
15 (28.85%)
| |
|
RF
|
13 (25%)
| |
|
Current treatment
|
|
Corticosteroids
|
40 (76.92%)
| |
|
Hydroxychloroquine
|
32 (61.54%)
| |
|
Cyclophosphamide
|
10 (19.23%)
| |
|
Cyclosporine
|
12 (23.07%)
| |
|
Methotrexate
|
2 (3.85%)
| |
|
Mycophenolate mofetil
|
4 (7.69%)
| |
|
Tripterygium wilfordii
|
6 (11.54%)
| |
|
Other immunosuppressant agent
|
2 (3.85%)
| |
|
Disease activity indexes
|
|
ESSPRI
|
3.14 ± 1.63
| |
|
ESSDRI
|
9.17 ± 6.08
| |
- Results are expressed as mean ± SD or number (%). ESR, erythrocyte sedimentation rate, CRP C-reactive protein, ANA antinuclear antibody, RF rheumatoid factor, ESSDAI EULAR SS disease activity index, ESSPRI EULAR SS patient reported index
